Samsung Biologics launches S-HiCon platform

High-concentration drug formulation development platform, S-HiCon.

Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, announced on Monday that it has launched the high-concentration drug formulation development platform, S-HiCon.

The platform meets the increasing demand for formulations that require smaller doses to achieve therapeutic effects, while also reducing storage and transportation costs, while Samsung Biologics uploaded a webinar video to its website to explain the platform and announce the launch. S-HiCon was previously officially unveiled for the first time at the Bio Japan event held from October 9th to 11th, 204, in Yokohama, Japan.

High-concentration drug formulations require smaller dosages compared to low-concentration formulations to achieve the same efficacy as low-concentration formulations, making them ideal for developing subcutaneous injections and ocular delivery injections.

Samsung Biologics, which develops and manufactures various pharmaceuticals on a contract development and manufacturing (CDMO) basis for global pharmaceutical and biotech companies, has now expanded its formulation development capabilities from low to ultra-high concentrations.

With the launch of S-HiCon, Samsung Biologics has now introduced four CDMO platforms in 2024, bringing its total number of technological platforms to nine.

“With the capability to provide formulation development services ranging from low to high concentrations, we expect to help clients enter the market more quickly,” Samsung Biologics CDO Development Center head Min Ho-sung said.

“We will continue to develop customized, innovative technologies and services tailored to our customers’ needs.”